{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+255686", "items" : [{"_about" : "http://data.parliament.uk/resources/1127292", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127292/answer", "answerText" : {"_value" : "
The manufacturer of Evorel transdermal patches has confirmed that supplies of all presentations are currently available. However, they have stated that in some cases supplies are slightly lower than normal and therefore they are applying restrictions on orders as a precaution to ensure limited stock is maintained.<\/p>
The Department is aware that the supplier of FemSeven Sequi patches is experiencing long term supply issues. As a result, they are expected to be out of stock until late 2019. We remain in regular contact with the company to resolve this as soon as possible.<\/p>
Supplies of other hormone replacement therapy transdermal patches continue to remain available and patients affected have been advised to discuss these alternative treatment options with their clinician.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-24T14:48:55.623Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Hormone Replacement Therapy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the availability of (a) Evorel and (b) Femseven sequi patches.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4418", "label" : {"_value" : "Biography information for Justin Madders"} } , "tablingMemberConstituency" : {"_value" : "Ellesmere Port and Neston"} , "tablingMemberPrinted" : [{"_value" : "Justin Madders"} ], "uin" : "255686"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }